We are thrilled to unveil Medrio 8.1, a more user-friendly platform we’ve designed in order to make our system simpler to navigate and perform the tasks necessary to conduct clinical trials
San Francisco, CA (PRWEB) April 23, 2013
Medrio, a leading EDC and eClinical SaaS provider for clinical research, announces the highly anticipated release of Medrio 8.1 with iPad support. In this release, the same powerful platform has been redesigned with a fresh new look and offers customers enhanced navigation for ease of use.
Highlights of the Medrio 8.1 with iPad support release:
- Most commonly used functions are more readily available
- New workflow-driven home screen with high-level summaries
- Enter and monitor data on-site with your iPad
- Manage your study remotely
“The new 8.1 Medrio user interface was thoughtfully designed and helps the user navigate the pages more intuitively,” said Ashleigh Wilson, Clinical Data Manager at Heartflow. “It allows me to find what I need with fewer clicks and less time spent scrolling. The addition of iPad support will help our monitors greatly in the field.”
“We are thrilled to unveil Medrio 8.1, a more user-friendly platform we’ve designed in order to make our system simpler to navigate and perform the tasks necessary to conduct clinical trials,” said Jeff Johnson, Medrio’s Director of Customer Experience. “We’ve also incorporated features to improve system performance and maintain our high level of reliability. This has been a collaborative effort and our customers are responding with a great deal of excitement about the new platform and superior usability.”
About Medrio, Inc.
Medrio offers an integrated eClinical Software as a Service (SaaS) platform with a fully hosted Electronic Data Capture (EDC) system that drastically reduces study timelines and costs by putting study managers in control of their studies. By enabling studies to be built completely online without the need for any custom development, Medrio eClinical software allows studies to be ready in days instead of weeks. Medrio has been used successfully in Phase I-IV trials, registries, and other clinical studies by a number of leading contract research organizations (CROs), as well as biopharmaceutical and device companies. Founded in 2005, Medrio is headquartered in the San Francisco Bay Area. For more information visit http://www.medrio.com.